Otrivine Junior Sine Conservans Abschwellend (Xylometazoline Hydrochloride)

Xylometazoline hydrochloride, the active ingredient in Otrivine Junior Sine Conservans Abschwellend, is a topical nasal decongestant presented as a nasal spray for intranasal use. It provides temporary relief of nasal congestion caused by colds, sinusitis or allergic rhinitis in children.

GNH USA supplies Otrivine Junior Sine Conservans Abschwellend as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline is used to alleviate nasal congestion by constricting blood vessels in the nasal mucosa.

- Common cold nasal congestion: reduces swelling of nasal passages for faster breathing. - Acute sinusitis nasal blockage: eases blockage to improve sinus drainage. - Allergic rhinitis in children: diminishes nasal swelling associated with allergy symptoms.

Xylometazoline may cause local and, rarely, systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing - Headache - Altered taste perception

Serious or Rare Side Effects: - Rebound nasal congestion after prolonged use - Severe hypertension or tachycardia - Anaphylactic reaction - Nasal ulceration or epistaxis

When using Xylometazoline nasal spray, observe the following precautions.

- Age restriction: not recommended for children under 6 months. - Duration limit: limit use to 3‑5 consecutive days to avoid rebound congestion. - Cardiovascular conditions: avoid in patients with uncontrolled hypertension or heart disease. - Nasal pathology: do not use in cases of severe nasal obstruction, ulceration or recent nasal surgery. - Drug interactions: consult a healthcare professional if using systemic sympathomimetics or MAO inhibitors. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Xylometazoline can interact with certain systemic medications; consider the following.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: may potentiate hypertensive response. - Systemic sympathomimetic agents (e.g., pseudoephedrine): additive vasoconstriction increasing blood pressure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia induced by Xylometazoline. - Oral antihypertensives: possible reduction in blood‑pressure‑lowering effect. - Other intranasal decongestants: increased risk of local irritation. - Antidepressants affecting norepinephrine: monitor for cardiovascular effects.